The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Findings indicate that dapagliflozin and calorie restriction together improve weight loss and metabolic health, increasing ...

Russell Wooten of Hendersonville, North Carolina, has spent much of his life struggling with obesity, often carrying 260 pounds on his 6-foot-3 frame. He repeatedly starved himself to lose weight, ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

Oprah Winfrey admitted two years ago to taking diabetes medication to lose weight. Now, in a new podcast episode, she ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

The following content is for informational purposes only. This article is not intended to be a substitute for profession ...